NASDAQ:BPMC Blueprint Medicines (BPMC) Stock Price, News & Analysis $86.43 -4.98 (-5.45%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$84.51▼$91.7650-Day Range$86.43▼$120.5052-Week Range$43.89▼$121.90Volume1.54 million shsAverage Volume704,941 shsMarket Capitalization$5.41 billionP/E RatioN/ADividend YieldN/APrice Target$120.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Blueprint Medicines alerts: Email Address Blueprint Medicines MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.74 Rating ScoreUpside/Downside38.8% Upside$120.00 Price TargetShort InterestHealthy6.47% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 6 Articles This WeekInsider TradingSelling Shares$13.07 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.99) to ($1.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.76 out of 5 starsMedical Sector345th out of 910 stocksPharmaceutical Preparations Industry148th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingBlueprint Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.74, and is based on 11 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageBlueprint Medicines has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Blueprint Medicines' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.47% of the outstanding shares of Blueprint Medicines have been sold short.Short Interest Ratio / Days to CoverBlueprint Medicines has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Blueprint Medicines has recently decreased by 8.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldBlueprint Medicines does not currently pay a dividend.Dividend GrowthBlueprint Medicines does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BPMC. Previous Next 2.0 News and Social Media Coverage News SentimentBlueprint Medicines has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Blueprint Medicines this week, compared to 5 articles on an average week.Search InterestOnly 1 people have searched for BPMC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Blueprint Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,065,852.00 in company stock.Percentage Held by InsidersOnly 4.21% of the stock of Blueprint Medicines is held by insiders.Read more about Blueprint Medicines' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Blueprint Medicines are expected to grow in the coming year, from ($3.99) to ($1.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Blueprint Medicines is -17.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Blueprint Medicines is -17.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBlueprint Medicines has a P/B Ratio of 17.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Blueprint Medicines' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About Blueprint Medicines Stock (NASDAQ:BPMC)Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Read More BPMC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BPMC Stock News HeadlinesAugust 9, 2024 | insidertrades.comPhilina Lee Sells 41,913 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) StockSeptember 7 at 1:11 AM | americanbankingnews.comHead to Head Survey: Blueprint Medicines (NASDAQ:BPMC) vs. Tonix Pharmaceuticals (NASDAQ:TNXP)September 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.September 2, 2024 | americanbankingnews.comBlueprint Medicines Co. (NASDAQ:BPMC) Given Average Recommendation of "Moderate Buy" by BrokeragesAugust 24, 2024 | stockhouse.comThe Schall Law Firm Is Investigating Blueprint Medicines Corporation For Securities Fraud And Stockholders With Losses Are Invited To ContributeAugust 20, 2024 | finance.yahoo.comInsider Sale: CFO Michael Landsittel Sells Shares of Blueprint Medicines Corp (BPMC)August 18, 2024 | finance.yahoo.comBPMC Sep 2024 95.000 put (BPMC240920P00095000)August 7, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)September 7, 2024 | Mode Mobile (Ad)Pre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A investment now open.August 2, 2024 | markets.businessinsider.comStrong Sales and Market Potential Affirm Buy Rating for Blueprint MedicinesAugust 2, 2024 | seekingalpha.comBlueprint Medicines Corporation (BPMC) Q2 2024 Earnings Call TranscriptAugust 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Blueprint Medicines Surpasses Q2 Revenue Estimates with Ayvakit’s SuccessAugust 1, 2024 | markets.businessinsider.comHold Rating on Blueprint Medicines Amid Strong Ayvakit Sales but Uncertain Long-Term ProspectsAugust 1, 2024 | msn.comBlueprint Medicines GAAP EPS of -$0.80 beats by $0.49, revenue of $138.16M beats by $34.22MAugust 1, 2024 | seekingalpha.comBlueprint Medicines Corporation 2024 Q2 - Results - Earnings Call PresentationAugust 1, 2024 | prnewswire.comBlueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue GuidanceJuly 26, 2024 | money.usnews.comBlueprint Medicines CorpJuly 18, 2024 | prnewswire.comBlueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024See More Headlines Receive BPMC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/01/2024Today9/07/2024Next Earnings (Estimated)10/24/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BPMC CUSIPN/A CIK1597264 Webwww.blueprintmedicines.com Phone(617) 374-7580FaxN/AEmployees640Year Founded2011Price Target and Rating Average Stock Price Target$120.00 High Stock Price Target$168.00 Low Stock Price Target$76.00 Potential Upside/Downside+38.8%Consensus RatingModerate Buy Rating Score (0-4)2.74 Research Coverage19 Analysts Profitability EPS (Most Recent Fiscal Year)($4.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-506,980,000.00 Net Margins-56.64% Pretax Margin-56.49% Return on Equity-157.30% Return on Assets-34.49% Debt Debt-to-Equity Ratio1.06 Current Ratio3.71 Quick Ratio3.65 Sales & Book Value Annual Sales$362.80 million Price / Sales14.92 Cash FlowN/A Price / Cash FlowN/A Book Value$5.06 per share Price / Book17.08Miscellaneous Outstanding Shares62,617,000Free Float59,981,000Market Cap$5.41 billion OptionableOptionable Beta0.63 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMs. Kathryn Haviland (Age 48)President, CEO & Director Comp: $1.17MMr. Alexis A. Borisy A.M. (Age 52)Co-Founder & Director Comp: $50kMr. Michael Landsittel (Age 52)Chief Financial Officer Comp: $785.36kMs. Tracey L. McCain Esq. (Age 56)Executive VP, Chief Legal & Compliance Officer and Secretary Comp: $764.9kDr. Fouad Namouni M.D. (Age 55)President of Research & Development Comp: $916.4kMs. Ariel Hurley (Age 50)Senior VP, Finance & Principal Accounting Officer Dr. Christopher K. Murray Ph.D. (Age 60)Senior VP of Technical Operations and Chief Technical Operations & Quality Officer Comp: $338.37kDr. Percy H. Carter M.B.A. (Age 53)Ph.D., Chief Scientific Officer Comp: $761.15kJenna CohenSenior Director & Head of Investor RelationsMs. Debra Durso-Bumpus (Age 54)Chief People Officer More ExecutivesKey CompetitorsForty SevenNASDAQ:FTSVTurning Point TherapeuticsNASDAQ:TPTXCelldex TherapeuticsNASDAQ:CLDXDeciphera PharmaceuticalsNASDAQ:DCPHSchrödingerNASDAQ:SDGRView All CompetitorsInsiders & InstitutionsClearbridge Investments LLCBought 220,980 shares on 8/27/2024Ownership: 0.353%Dana Investment Advisors Inc.Bought 1,114 shares on 8/27/2024Ownership: 0.024%Novo Holdings A SSold 183,626 shares on 8/20/2024Ownership: 0.279%Algert Global LLCBought 29,330 shares on 8/16/2024Ownership: 0.105%Creative PlanningBought 2,636 shares on 8/16/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions BPMC Stock Analysis - Frequently Asked Questions How have BPMC shares performed this year? Blueprint Medicines' stock was trading at $92.24 at the beginning of the year. Since then, BPMC shares have decreased by 6.3% and is now trading at $86.43. View the best growth stocks for 2024 here. How were Blueprint Medicines' earnings last quarter? Blueprint Medicines Co. (NASDAQ:BPMC) announced its earnings results on Thursday, August, 1st. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the consensus estimate of ($1.29) by $0.49. The business's quarterly revenue was up 139.9% compared to the same quarter last year. What is Kate Haviland's approval rating as Blueprint Medicines' CEO? 16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend. When did Blueprint Medicines IPO? Blueprint Medicines (BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Blueprint Medicines' major shareholders? Blueprint Medicines' top institutional investors include William Blair Investment Management LLC (2.55%), American Century Companies Inc. (1.28%), Millennium Management LLC (1.00%) and Hood River Capital Management LLC (0.80%). Insiders that own company stock include Jeffrey W Albers, Kate Haviland, Christina Rossi, Fouad Namouni, Tracey L Mccain, Michael Landsittel, Debra Durso-Bumpus, Percy H Carter, Christopher K Murray, Philina Lee, L Becker Hewes, Ariel Hurley, George Demetri and Mark Alan Goldberg. View institutional ownership trends. How do I buy shares of Blueprint Medicines? Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Blueprint Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD) and QUALCOMM (QCOM). This page (NASDAQ:BPMC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Blueprint Medicines Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Blueprint Medicines With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
